Maxim Group initiated coverage on NLS Pharmaceutics with a new price target
$NLSP
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
425 - NLS Pharmaceutics Ltd. (0001783036) (Subject)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 million equity financing of preferred shares (or equivalents) and warrants from March 2025. Pursuant to the second closing, the Company agreed to issue 606,061 preferred shares (or equivalent) at a conversion price of $1.65 per share, representing a 10% premium to the market share
ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders. Dear Shareholders, We are delighted to share a summary of NLS Pharmaceutics' achieved milestones since the fourth quarter of 2024. Here's a snapshot of our progress and what lies ahead: 1. Completion of Major Financing Events During the first quarter of 2025, we initially closed two equity financing transactions, resulting in aggregate gross proceeds of $2.5 million, priced at $3.10 and $1.65 per share at a premium to the market share p
Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy ZURICH, April 15, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced positive results from Study KO-943, a preclinical investigation evaluating the efficacy of Mazindol in mitigating fentanyl-induced conditioned place preference (CPP) in mice. The study, conducted by Key-Obs SAS, a leading precl
Brookline Capital initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00
Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disordersProfessor Florence Allouche Aknin, PharmD, MBA, is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraisingZURICH, SWITZERLAND / ACCESSWIRE / November 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that, subject to final ap
ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:NLS Pharmaceutics CEO Issues Letter to ShareholdersTo our Shareholders and Friends,Though we may have been quiet recently, I wanted to assure you that the team here at NLS has been very busy behind the scenes ensuring that we realize our vision of awakening a brighter future for pa
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer ("CFO"). A versatile strategic leader within healthcare, Mr. Dewedoff brings more than 20 years of experience in the life sciences industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Mr. Dewedoff also serves as a CFO and Advisor fo
SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)